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How similar are biosimilars?
They are likely to be cost effective
Jeffrey K Aronson honorary consultant physician 1, Robin E Ferner director 2
1Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford OX2 6GG, UK; 2West Midlands Centre for
Adverse Drug Reactions, City Hospital, Birmingham, UK
The United Kingdom has lagged behind other European
countries in adopting biosimilars, said a recent article in the
Financial Times,1 and a British Biosimilars Association has
been launched “to promote medicines that could shave a third
off NHS prices.”2 The UK’s chief pharmaceutical officer was
quoted as saying that “biosimilar medicines have enormous
potential to deliver increased patient access, as well as savings
to the NHS, which can be reinvested elsewhere.”2
Biological products (“biologics”) include vaccines, blood and
blood components, somatic cells, tissues (such as corneas, skin,
and spermatozoa), and recombinant proteins.3 They can be
composed of sugars (such as heparin), proteins (monoclonal
antibodies), nucleic acids (antisense oligonucleotides), or
combinations of these (fusion proteins), but their precise
structures are often not easily characterised.
Not like generics
Biosimilars are defined as biologics that are similar to other
biologics already authorised for use.4 When biosimilar proteins
are synthesised, the primary amino acid sequence is likely to
be preserved, but there can be differences in glycosylation,
deamination, or oxidation and in the three dimensional structure,
which can affect the interaction of the protein with other
molecules. Because of such differences the World Health
Organization introduced a nomenclature that involved qualifying
with Greek letters the names of some compounds made
recombinantly by different manufacturers: follitropin alfa, beta,
and gamma and epoetin alfa, beta, theta, and zeta are examples.5
One highly glycosylated epoetin was given a different name
altogether, darbepoetin.
Biosimilars should not be regarded as generic equivalents of
originator medicinal products, because they are complex
molecules, expected to differ more from the originator molecules
than generic versions of non-biologics. One cannot be sure that
two biosimilars will have similar benefits and harms. Head to
head comparisons of biosimilars are infrequent, and indirect
comparisons may be inadequate. For example, in a network
meta-analysis of the effects of biosimilars of epoetin the authors
reported that the comparative benefits and harms of the different
compounds were very uncertain.6
Nevertheless, regulators and market authorisation holders
generally take considerable care to ensure that biosimilars are
(as the European Medicines Agency states) “highly similar to
the reference medicinal product in physicochemical and
biological terms,”7 under principles laid down by the
International Conference on Harmonization,8 the EMA,8 and
the US Food and Drug Administration.9 These include, for
example, demonstrably similar pharmacokinetic and
pharmacodynamic properties and being used in the same dosage
as the originator product. The UK National Institute for Health
and Care Excellence (NICE) has provisions for recommending
biosimilars when appropriate.10
Prescribing cheaper biosimilars might save the NHS an
estimated 10% of the cost of the relevant biologics, a probable
worthwhile saving, as biologics are often very expensive. For
example, the NHS spent over £140m (€178m; $200m) on the
tumour necrosis factor alfa inhibitor infliximab in 2013-14,
some 15 years after it was first marketed as Remicade; NICE
has since recommended the use of two infliximab biosimilars,
Remsima and Inflectra,11-13 both of which have been thoroughly
evaluated. They are identical to the originator product in
pharmaceutical form, strength, composition, and route of
administration. The physicochemical and biological characters,
possible contaminants and impurities, and stability of Remsima
have been reported.14 Comparison of its biological actions with
those of the originator product showed only minor differences
in relative binding affinities for the FcγRIIIa receptor subtype,
for example, and these seemed to be biologically insignificant.
The pharmacokinetics were almost identical, and clinical
markers of disease activity responded equally well to the
reference and biosimilar products in patients with rheumatoid
arthritis or ankylosing spondylitis. Finally, in a 54 week
comparative study the two products were therapeutically
equivalent when combined with methotrexate in patients with
rheumatoid arthritis.
When evidence of this kind is available, there should not be
undue concern over starting treatment with a biosimilar rather
than the originator drug, although switching between products
might not be straightforward.
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Naming problems
Naming and prescribing biosimilars also create problems. An
estimated 30 biologics, with combined sales of $51bn (£35bn;
€45bn), came off patent in 2015,15 opening the door to
biosimilars. The task of naming them has therefore become
crucial, and countries have adopted different methods. WHO
has proposed a voluntary scheme in whichmost biologics would
be given a “biological qualifier,” a random four letter code and
an optional two digit check sum, tied to the place of
manufacture. However, the system is highly controversial, partly
because the codes are meaningless.16 17
In the meantime, the advice on prescribing biosimilars is to use
the brand name of your preferred product. After treatment has
begun, the same product should continue to be used, if possible,
because of potential small differences between biosimilars,
which cannot be considered to be completely interchangeable.18
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